AstronauTx launches to target astrocytes for Alzheimer's

AstronauTx is looking to go beyond the amyloid/tau paradigm in Alzheimer's disease with £6.5 million ($7.8 million) in seed capital to develop therapies that modulate astrocyte function.

The newco raised the capital from the Dementia Discovery Fund, the dementia-focused venture fund that last year closed its fund at £250 million...